167 related articles for article (PubMed ID: 15931286)
1. Recombinant TSH-stimulated, radioguided differentiated thyroid carcinoma surgery.
Spieth ME; Standiford SB; Starkman ME; Gough J
Clin Med Res; 2003 Jan; 1(1):53-6. PubMed ID: 15931286
[TBL] [Abstract][Full Text] [Related]
2. [Recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma].
Gómez Camarero P; Martínez Brocca MA; Rodríguez Rodríguez JR; Navarro González E; Tirado Hospital JL; González Duarte D; Vázquez Albertino R; Astorga Jimenez R
Rev Esp Med Nucl; 2003; 22(5):295-305. PubMed ID: 14534005
[TBL] [Abstract][Full Text] [Related]
3. Clinical experience with recombinant human thyrotrophin (rhTSH) in the management of patients with differentiated thyroid cancer.
Mariani G; Ferdeghini M; Augeri C; Villa G; Taddei GZ; Scopinaro G; Boni G; Bodei L; Rabitti C; Molinari E; Bianchi R
Cancer Biother Radiopharm; 2000 Apr; 15(2):211-7. PubMed ID: 10803328
[TBL] [Abstract][Full Text] [Related]
4. A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation.
Robbins RJ; Larson SM; Sinha N; Shaha A; Divgi C; Pentlow KS; Ghossein R; Tuttle RM
J Nucl Med; 2002 Nov; 43(11):1482-8. PubMed ID: 12411552
[TBL] [Abstract][Full Text] [Related]
5. Are there disadvantages in administering 131I ablation therapy in patients with differentiated thyroid carcinoma without a preablative diagnostic 131I whole-body scan?
Salvatori M; Perotti G; Rufini V; Maussier ML; Dottorini M
Clin Endocrinol (Oxf); 2004 Dec; 61(6):704-10. PubMed ID: 15579184
[TBL] [Abstract][Full Text] [Related]
6. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
[TBL] [Abstract][Full Text] [Related]
7. The role of technetium-99m methoxyisobutylisonitrile scintigraphy in the planning of therapy and follow-up of patients with differentiated thyroid carcinoma after surgery.
Rubello D; Mazzarotto R; Casara D
Eur J Nucl Med; 2000 Apr; 27(4):431-40. PubMed ID: 10805117
[TBL] [Abstract][Full Text] [Related]
8. Recombinant human thyrotropin (rhTSH) in the management of differentiated thyroid cancer.
Durski JM; Weigel RJ; McDougall IR
Nucl Med Commun; 2000 Jun; 21(6):521-8. PubMed ID: 10894560
[TBL] [Abstract][Full Text] [Related]
9. Association between residual thyroid carcinoma and diffuse hepatic uptake of 131I following radioiodine ablation in postoperative total thyroidectomy patients.
Tatar FA; Morita E; Ituarte PH; Cavalieri RR; Duh QY; Price DC; Siperstein AE; Clark OH
World J Surg; 2001 Jun; 25(6):718-22. PubMed ID: 11376405
[TBL] [Abstract][Full Text] [Related]
10. Surgery and radioablation therapy combined: introducing a 1-week-condensed procedure bonding total thyroidectomy and radioablation therapy with recombinant human TSH.
Emmanouilidis N; Müller JA; Jäger MD; Kaaden S; Helfritz FA; Güner Z; Kespohl H; Knitsch W; Knapp WH; Klempnauer J; Scheumann GF
Eur J Endocrinol; 2009 Nov; 161(5):763-9. PubMed ID: 19687168
[TBL] [Abstract][Full Text] [Related]
11. Neck and whole-body scanning with 5-mCi dose of (123)I as diagnostic tracer in patients with well-differentiated thyroid cancer.
Gulzar Z; Jana S; Young I; Bukberg P; Yen V; Naddaf S; Abdel-Dayem HM
Endocr Pract; 2001; 7(4):244-9. PubMed ID: 11497474
[TBL] [Abstract][Full Text] [Related]
12. [The early detection of metastatic differentiated thyroid cancer using 131I total body scan and treatment with 131I].
Ikekubo K; Hino M; Ito H; Yamaguchi H; Saiki Y; Ui K; Tominaga E; Nakanishi M; Kawai J; Koh T
Kaku Igaku; 1991 Mar; 28(3):247-59. PubMed ID: 1904509
[TBL] [Abstract][Full Text] [Related]
13. Timing of post 131I ablation diagnostic whole body scan in differentiated thyroid cancer patients. Less than four months post ablation may be too early.
Winter M; Winter J; Heinzel A; Behrendt FF; Krohn T; Mottaghy FM; Verburg FA
Nuklearmedizin; 2015; 54(4):151-7. PubMed ID: 26028188
[TBL] [Abstract][Full Text] [Related]
14. Radioiodine treatment with 30 mCi after recombinant human thyrotropin stimulation in thyroid cancer: effectiveness for postsurgical remnants ablation and possible role of iodine content in L-thyroxine in the outcome of ablation.
Barbaro D; Boni G; Meucci G; Simi U; Lapi P; Orsini P; Pasquini C; Piazza F; Caciagli M; Mariani G
J Clin Endocrinol Metab; 2003 Sep; 88(9):4110-5. PubMed ID: 12970272
[TBL] [Abstract][Full Text] [Related]
15. Reproducibility of whole-body 131I scan and serum thyrotropin and stimulated thyroglobulin values in patients studied twice after injection of recombinant human thyrotropin.
Niederkohr RD; McDougall IR
Eur J Nucl Med Mol Imaging; 2007 Mar; 34(3):363-7. PubMed ID: 17021814
[TBL] [Abstract][Full Text] [Related]
16. Patients with differentiated thyroid cancer who underwent radioiodine thyroid remnant ablation with low-activity ¹³¹I after either recombinant human TSH or thyroid hormone therapy withdrawal showed the same outcome after a 10-year follow-up.
Molinaro E; Giani C; Agate L; Biagini A; Pieruzzi L; Bianchi F; Brozzi F; Ceccarelli C; Viola D; Piaggi P; Vitti P; Pacini F; Elisei R
J Clin Endocrinol Metab; 2013 Jul; 98(7):2693-700. PubMed ID: 23626005
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic use of recombinant human thyrotropin in patients with thyroid carcinoma (phase I/II study).
Meier CA; Braverman LE; Ebner SA; Veronikis I; Daniels GH; Ross DS; Deraska DJ; Davies TF; Valentine M; DeGroot LJ
J Clin Endocrinol Metab; 1994 Jan; 78(1):188-96. PubMed ID: 8288703
[TBL] [Abstract][Full Text] [Related]
18. A comparison of recombinant human thyrotropin and thyroid hormone withdrawal for the detection of thyroid remnant or cancer.
Haugen BR; Pacini F; Reiners C; Schlumberger M; Ladenson PW; Sherman SI; Cooper DS; Graham KE; Braverman LE; Skarulis MC; Davies TF; DeGroot LJ; Mazzaferri EL; Daniels GH; Ross DS; Luster M; Samuels MH; Becker DV; Maxon HR; Cavalieri RR; Spencer CA; McEllin K; Weintraub BD; Ridgway EC
J Clin Endocrinol Metab; 1999 Nov; 84(11):3877-85. PubMed ID: 10566623
[TBL] [Abstract][Full Text] [Related]
19. Interrupted 131I Procedures for Patients With Differentiated Thyroid Cancer: Comparing Thyroxine Withdrawal With Recombinant Thyrotropin Preparation Techniques.
Karls S; Abikhzer G; Tamilia M; Probst S
Clin Nucl Med; 2017 Apr; 42(4):247-249. PubMed ID: 28166158
[TBL] [Abstract][Full Text] [Related]
20. Radioiodine ablation of post-surgical thyroid remnants after preparation with recombinant human TSH: why, how and when.
Barbaro D; Boni G
Eur J Surg Oncol; 2007 Jun; 33(5):535-40. PubMed ID: 17337154
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
